Avantax Advisory Services Inc. Has $467,000 Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Avantax Advisory Services Inc. lifted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 23.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 9,766 shares of the biopharmaceutical company’s stock after purchasing an additional 1,839 shares during the quarter. Avantax Advisory Services Inc.’s holdings in Halozyme Therapeutics were worth $467,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the business. GSA Capital Partners LLP acquired a new position in shares of Halozyme Therapeutics in the third quarter valued at approximately $217,000. Advisors Asset Management Inc. boosted its stake in Halozyme Therapeutics by 5.8% in the 3rd quarter. Advisors Asset Management Inc. now owns 39,646 shares of the biopharmaceutical company’s stock worth $2,269,000 after purchasing an additional 2,174 shares during the period. Intech Investment Management LLC boosted its stake in Halozyme Therapeutics by 147.4% in the 3rd quarter. Intech Investment Management LLC now owns 56,305 shares of the biopharmaceutical company’s stock worth $3,223,000 after purchasing an additional 33,542 shares during the period. Alpha DNA Investment Management LLC increased its holdings in Halozyme Therapeutics by 11.1% during the 3rd quarter. Alpha DNA Investment Management LLC now owns 9,414 shares of the biopharmaceutical company’s stock worth $539,000 after purchasing an additional 938 shares in the last quarter. Finally, Centaurus Financial Inc. acquired a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at about $127,000. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Price Performance

Shares of HALO opened at $65.16 on Monday. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. The company’s fifty day simple moving average is $58.20 and its 200 day simple moving average is $54.66. Halozyme Therapeutics, Inc. has a 1-year low of $37.73 and a 1-year high of $65.53. The company has a market cap of $8.05 billion, a price-to-earnings ratio of 19.00, a PEG ratio of 0.42 and a beta of 1.32.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The company had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. On average, research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Benchmark reaffirmed a “buy” rating and set a $75.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Wells Fargo & Company cut their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Finally, Piper Sandler increased their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 10th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $62.78.

Insiders Place Their Bets

In other news, SVP Michael J. Labarre sold 1,697 shares of the firm’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the sale, the senior vice president now owns 173,756 shares in the company, valued at approximately $10,126,499.68. This trade represents a 0.97 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the sale, the director now directly owns 43,611 shares of the company’s stock, valued at $2,180,986.11. The trade was a 18.65 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 31,697 shares of company stock valued at $1,754,451 over the last 90 days. 2.40% of the stock is currently owned by insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.